Sansheng pharmaceutical: new gout drug sss11 obtained CFDA clinical trial application approval

Recently, Sansheng pharmaceutical announced that its new product, pegylated recombinant uric acid oxidase pegsiticase (sss11), has obtained the approval document for clinical trials of new drugs issued by the State Food and drug administration It is reported that sss11 is a kind of Candida prion Utilis's pegylated recombinant uric acid oxidase, which is modified by linking multiple 20 kilodalton molecular weight polyethylene glycol (PEG), is used to treat refractory gout or tumor lysis syndrome Both are characterized by hyperuricemia (increased concentration of uric acid) Sansheng pharmaceutical owns the global intellectual property rights of sss11 and has granted the intellectual property rights of sss11 in the United States to selecta Biosciences, Inc according to a one-to-one clinical study conducted by selecta Biosciences, Inc in the United States, sss11 can significantly reduce uric acid through intravenous infusion and intramuscular injection, and its safety and tolerance are good Lou Jing, chairman of Sansheng Pharmaceutical Group, said: the approval of clinical trials will enable us to carry out sss11 phase I to phase III clinical trials smoothly at the beginning of this year, providing more treatment options for gout patients Next, Sansheng pharmaceutical will continue to look for opportunities to develop more therapeutic biological agents in urgent need, especially the core treatment area of Sansheng Pharmaceutical Group: swelling Oncology, rheumatology, Nephrology, metabolism and dermatology.